Who we are


Delivery of drugs to the lung has a long history and modern inhaled medicines have revolutionised the treatment of a number of respiratory diseases (e.g. asthma, COPD, cystic fibrosis). The lung also offers exciting opportunities for delivery of other drug modalities based on biologics (e.g. peptides/proteins, siRNA, vaccines etc.). Meeting the performance, stability and manufacturability requirements for these complex drug products for a broad patient demographic (age, disease state etc.) presents a challenge to the product developer which improved mechanistic understanding is helping to address. The APS Inhalation Focus Group was established as a forum to facilitate interaction between scientists engaged in the research, development, manufacture and regulation of inhaled drug products.

The aims of the Inhalation Focus Group are to:

  • Provide a forum for Industry, Academia and the Regulators to engage in discussion of current issues in the science, technology & regulation pertinent to pulmonary and nasal drug delivery.
  • Collaborate and coordinate with other relevant organizations active in the field (e.g. Aerosol Society (DDL), EPAG, AAPS,HESI and RDD) with a view to reviewing current ‘hot topics’ in the field and establishing joint meetings, dialogue and scientific consensus.
  • Provide continuing education for the membership through training symposia, focussed 1-2 day workshops/seminars, webinars

Eddie French is an independent pharmaceutical consultant who specializes in therapeutic product design and development. He has significant experience of both large and small molecules, and drug delivery devices. In this role he provides support to numerous UK and international companies and philanthropic organisations. He is a previous chair of APSGB and is a visiting professor of Formulation Science at the University of Nottingham.

Jeremy Clarke is currently Senior Fellow, Pharma Supply Chain Technical at GSK working on technology transfer, industrialisation of late stage development candidates in the respiratory portfolio, as well as life cycle management programmes for marketed products and advocacy in science/regulation of Orally Inhaled Drug Products (OIPs).